<div id="readability-page-1"><article>WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: <ul type="disc"><li>Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.</li><li>The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with a gross profit of approximately $90 thousand in the first quarter of 2025.</li><li>Operating expenses were approximately $2.17 million in the first quarter of 2026, compared with approximately $2.09 million in the first quarter of 2025.</li><li>Net loss attributable to common shareholders in the first quarter of 2026 was approximately $2.21 million, or a net loss of $1.28 per share, compared with a net loss of approximately $2.00 million, or a net loss of $6.25 per share, in the first quarter of 2025.</li></ul> About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine) in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Australian Chestnut Extract and/or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke SheilaBurke-consultant@60degreespharma.com (484) 667-6330 Investor Contact: Patrick Gaynes patrickgaynes@60degreespharma.com (310) 989-5666 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1USXpNaU0zTmpBME9URXlJekl4T0RJek16Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1USXpNaU0zTmpBME9URXlJekl4T0RJek16Zz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png"/></article></div>

SXTP

SBIO

LABU

60 Degrees Pharmaceuticals, Inc. reported its Q1 2026 financial results, showing a slight decrease in net product revenues to $162,000 and a gross profit of $76,000. Operating expenses rose to $2.17 million, leading to a net loss of $2.21 million, or $1.28 per share. The company specializes in developing medicines for infectious diseases and has FDA approval for its lead product, ARAKODA®.

StockTitan

60 Degrees Pharmaceuticals

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VG Health

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results | SXTP Stock News